Oct 04, 2018
We would like to take this opportunity to thank everyone who has invested their time and effort to the treatment of lymphangioma patients around the world.
In 2009, Chugai temporarily suspended the global development of OK-432. From that time, a humanitarian aid program was established to provide treatment free of charge to patients of lymphangioma at medical institutions in certain countries.
After careful examination of the various factors impacting the global development of OK-432, including an evaluation of changes in the business environment, revisions to the product life cycle, relevant pharmaceutical regulations, and stricter approval criteria, Chugai has officially decided to suspend any further development of OK-432.
In accordance with this decision, it was concluded that continuing to provide products that are no longer in global development does not align with the objective of each relevant country’s “compassionate use system”.
Therefore, it is our responsibility to inform all interested parties that the OK-432 Program has now been discontinued.
Chugai Pharmaceutical Co., Ltd.